Compare Stocks: ARVN, PVLA, SRPT, and AUPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$8.29	$8.72	$6.97 ▼ $14.51	$534.88M	1.75	769,115 shs	1.78 million shs
AUPH Aurinia Pharmaceuticals	$16.90	$15.87	$10.34 ▼ $19.25	$2.25B	1.4	775,046 shs	1.20 million shs
PVLA Palvella Therapeutics	$150.56	$149.44	$56.22 ▼ $161.38	$2.17B	-0.25	210,924 shs	646,460 shs
SRPT Sarepta Therapeutics	$20.11	$18.62	$14.68 ▼ $25.32	$2.12B	0.27	3.17 million shs	6.29 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	0.00%	-1.89%	-11.43%	+7.11%	+10.24%
AUPH Aurinia Pharmaceuticals	0.00%	+4.97%	+1.50%	-3.59%	+30.00%
PVLA Palvella Therapeutics	0.00%	+0.29%	+6.00%	+26.69%	+158.52%
SRPT Sarepta Therapeutics	0.00%	-1.66%	+7.03%	+13.94%	+15.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$8.29	$8.72	$6.97 ▼ $14.51	$534.88M	1.75	769,115 shs	1.78 million shs
AUPH Aurinia Pharmaceuticals	$16.90	$15.87	$10.34 ▼ $19.25	$2.25B	1.4	775,046 shs	1.20 million shs
PVLA Palvella Therapeutics	$150.56	$149.44	$56.22 ▼ $161.38	$2.17B	-0.25	210,924 shs	646,460 shs
SRPT Sarepta Therapeutics	$20.11	$18.62	$14.68 ▼ $25.32	$2.12B	0.27	3.17 million shs	6.29 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	0.00%	-1.89%	-11.43%	+7.11%	+10.24%
AUPH Aurinia Pharmaceuticals	0.00%	+4.97%	+1.50%	-3.59%	+30.00%
PVLA Palvella Therapeutics	0.00%	+0.29%	+6.00%	+26.69%	+158.52%
SRPT Sarepta Therapeutics	0.00%	-1.66%	+7.03%	+13.94%	+15.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.27	Hold	$14.17	70.89% Upside
AUPH Aurinia Pharmaceuticals	2.67	Moderate Buy	$17.67	4.54% Upside
PVLA Palvella Therapeutics	3.00	Buy	$209.14	38.91% Upside
SRPT Sarepta Therapeutics	2.15	Hold	$25.69	27.73% Upside

Current Analyst Ratings Breakdown

Latest ARVN, PVLA, SRPT, and AUPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	SRPT Sarepta Therapeutics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell
9/8/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/3/2026	ARVN Arvinas	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/26/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/20/2026	AUPH Aurinia Pharmaceuticals	Bloom Burton Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/19/2026	SRPT Sarepta Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D) ➝ Sell (E+)
8/13/2026	ARVN Arvinas	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D)
8/12/2026	AUPH Aurinia Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C+)
8/12/2026	SRPT Sarepta Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/10/2026	ARVN Arvinas	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$10.00
8/10/2026	ARVN Arvinas	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$14.00

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$316.70M	1.69	N/A	N/A	$6.76 per share	1.23
AUPH Aurinia Pharmaceuticals	$283.05M	7.94	$1.01 per share	16.68	$4.41 per share	3.83
PVLA Palvella Therapeutics	$42.81M	50.68	N/A	N/A	$2.36 per share	63.80
SRPT Sarepta Therapeutics	$2.20B	0.97	N/A	N/A	$10.89 per share	1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$80.80M	$0.10	82.91	N/A	N/A	2.94%	1.91%	1.29%	11/4/2026 (Estimated)
AUPH Aurinia Pharmaceuticals	$287.20M	$2.29	7.38	15.65	N/A	100.84%	26.11%	19.89%	11/3/2026 (Estimated)
PVLA Palvella Therapeutics	-$41.72M	-$4.83	N/A	N/A	N/A	N/A	-47.84%	-38.33%	11/10/2026 (Estimated)
SRPT Sarepta Therapeutics	-$713.41M	-$2.90	N/A	11.05	0.29	-13.48%	-1.60%	-0.66%	11/4/2026 (Estimated)

Latest ARVN, PVLA, SRPT, and AUPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	AUPH Aurinia Pharmaceuticals	$0.24	$0.28	+$0.04	$0.28	$80.45 million	$58.57 million
8/5/2026	Q2 2026	SRPT Sarepta Therapeutics	$0.2173	$0.64	+$0.4227	-$0.05	$366.39 million	$401.25 million
8/4/2026	Q2 2026	ARVN Arvinas	-$0.3741	$2.58	+$2.9541	$2.58	$60.71 million	$249.70 million
8/4/2026	Q2 2026	PVLA Palvella Therapeutics	-$1.17	-$1.52	-$0.35	-$1.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
SRPT Sarepta Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	7.91	7.91
AUPH Aurinia Pharmaceuticals	0.07	5.42	4.97
PVLA Palvella Therapeutics	N/A	21.18	21.18
SRPT Sarepta Therapeutics	0.55	4.42	2.62

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
AUPH Aurinia Pharmaceuticals	36.83%
PVLA Palvella Therapeutics	40.11%
SRPT Sarepta Therapeutics	86.68%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	7.30%
AUPH Aurinia Pharmaceuticals	10.40%
PVLA Palvella Therapeutics	17.20%
SRPT Sarepta Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	246	64.52 million	59.81 million	Optionable
AUPH Aurinia Pharmaceuticals	128	133.05 million	119.21 million	Optionable
PVLA Palvella Therapeutics	29	14.41 million	11.93 million	N/A
SRPT Sarepta Therapeutics	835	105.63 million	98.34 million	Optionable

ARVN, PVLA, SRPT, and AUPH Headlines

Recent News About These Companies

Sarepta Therapeutics stock gains analyst support after mixed rating signals

September 20 at 6:45 PM | ad-hoc-news.deA

Sarepta Therapeutics stock holds near USD 19.76 after analyst reset

September 19 at 11:58 PM | ad-hoc-news.deA

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Brokerages

September 18 at 2:15 AM | americanbankingnews.com

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by Brokerages

September 18 at 2:13 AM | marketbeat.com

Squarepoint Ops LLC Has $1.51 Million Stock Position in Sarepta Therapeutics, Inc. $SRPT

September 16, 2026 | marketbeat.com

Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics

September 15, 2026 | finance.yahoo.com

Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near

September 15, 2026 | marketbeat.com

Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

September 14, 2026 | seekingalpha.com

Sarepta Therapeutics Drops 5.5% Amid Sector-Wide Selling

September 10, 2026 | news.alphastreet.comN

Sarepta Therapeutics (NASDAQ:SRPT) Shares Down 6.6% - Here's Why

September 10, 2026 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $4 Million Holdings in Sarepta Therapeutics, Inc. $SRPT

September 10, 2026 | marketbeat.com

Sarepta Therapeutics climbs 10%, rebounding from recent slide

September 9, 2026 | seekingalpha.com

Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 10.3% - Here's Why

September 9, 2026 | marketbeat.com

Sarepta Therapeutics (SRPT) Plunges 10.3% to $20.18

September 8, 2026 | news.alphastreet.comN

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

September 8, 2026 | benzinga.com

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

September 8, 2026 | benzinga.com

Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers

September 8, 2026 | reuters.com

Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Down - Should You Sell?

September 8, 2026 | marketbeat.com

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

September 8, 2026 | finance.yahoo.com

Jupiter Topco LLC Takes Position in Sarepta Therapeutics, Inc. $SRPT

September 7, 2026 | marketbeat.com

The Manufacturers Life Insurance Company Makes New $927,000 Investment in Sarepta Therapeutics, Inc. $SRPT

September 6, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, PVLA, SRPT, and AUPH Company Descriptions

Arvinas NASDAQ:ARVN

$8.29 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$8.25 -0.04 (-0.47%)

As of 04:09 AM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Aurinia Pharmaceuticals NASDAQ:AUPH

$16.90 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$16.91 +0.01 (+0.08%)

As of 04:00 AM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Palvella Therapeutics NASDAQ:PVLA

$150.56 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$150.69 +0.13 (+0.09%)

As of 06:00 AM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Sarepta Therapeutics NASDAQ:SRPT

$20.11 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$20.05 -0.06 (-0.32%)

As of 05:37 AM Eastern

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARVN, PVLA, SRPT, and AUPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARVN, PVLA, SRPT, and AUPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARVN, PVLA, SRPT, and AUPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, PVLA, SRPT, and AUPH Company Descriptions

Arvinas NASDAQ:ARVN

Aurinia Pharmaceuticals NASDAQ:AUPH

Palvella Therapeutics NASDAQ:PVLA

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARVN, PVLA, SRPT, and AUPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARVN, PVLA, SRPT, and AUPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARVN, PVLA, SRPT, and AUPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARVN, PVLA, SRPT, and AUPH Company Descriptions

Arvinas NASDAQ:ARVN

Aurinia Pharmaceuticals NASDAQ:AUPH

Palvella Therapeutics NASDAQ:PVLA

Sarepta Therapeutics NASDAQ:SRPT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools